Portal de Periódicos da CAPES

Survival analysis of patients with pancreatic cancer

2019; Elsevier BV; Volume: 21; Linguagem: Inglês

10.1016/j.hpb.2019.10.2142

1477-2574

Vladimir S. Trifanov, Oleg I. Kit, Evgeny Kolesnikov, Lubov' Yu Vladimirova, Christina Novoselova, Natalya A Abramova, Anna Storojakova, Aza Lyuanova, T. A. Snezhko, Е. А. Калабанова,

Advanced Breast Cancer Therapies

Introduction: Aim: was to analyze the survival rates of patients with pancreatic cancer. Method: The clinical data in patients with pancreatic malignant neoplasms from 2013 to 2018 has been examined based on materials of Rostov Scientific and Research Institute of Oncology, Russia. Overall survival has been calculated by the Kaplan-Meier method. Result: 133 cases patients with pancreatic cancer have been analysed. In 19.6% of cases the IIA stage of the disease has been established (26 patients), in 24.1% of cases - IIB (32 patients), in 21.8% of cases - III (29 patients), in 34.6% of cases - IV stage (46 patients). The survival median was 7 months (95% CI1-11.8). The probability that the patient will live for more than 22 months was 0.22., the probability that the patient will live for more than 12 months is 0.45, the standard error of the survival function is 0.08. A statistically significant difference in OS (overall survival) rates was found depending on the presence or absence of surgical treatment in the history. By 36 months of follow-up, if there was a surgical treatment in the history, the cumulative rate of survivors was 0.25, and in the absence it was 0 (p = 0.017). The survival median in the first case was 7 months (95% CI 6.4–12.4), in the second - 6 months (95% CI 6.5–13.7). Depending on the initial stage of the disease, the cumulative share of survivors by the 20 months of follow-up was: at the stage IIA - 0.75, IIB - 0.4, III - 0.43, IV - 0.15 (p =0.05). Conclusion: The highest OS was observed in patients with a history of surgical treatment, with the initial stage of the disease, who received GEM/GEMCAP or FOLFIRI/FOLFIRINOX regimens as part of first-line therapy.